A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Inclusion Criteria

• Age ≥18 years.
• ECOG performance status of 0 or 1.
• Histologically confirmed:
• Clear cell renal cell carcinoma (ccRCC).
• Diffuse large B-cell lymphoma (DLBCL, NOS).
• High-grade B-cell lymphoma (HGBCL).
• Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
• Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
• Disease progression, relapse, or refractory to prior therapy:
• ccRCC: ≥1 prior line incl. ICI + TKI.
• DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
• PTCL/CTCL: ≥1 prior systemic therapy.
• Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
• Tumor tissue available for central testing.

Exclusion Criteria

• Untreated or progressive CNS disease unless previously treated and stable.
• Other active invasive malignancy within 2 years (except certain low-risk cancers).
• Prior CD70-targeting therapy, including CAR T.
• ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
• Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
• Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
• Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
• Pregnancy, breastfeeding, or unwillingness to use effective contraception. Other protocol-defined Inclusion/Exclusion Criteria may apply.